KMT2A and acute lymphoblastic leukemia: As an additional target in MLL-ALL cells resistant to the combination treatment, we focused on anti-apoptosis pathway which was enriched in MLL-ALL-initiating cells compared with normal HSPCs (Fig. 2a).